ew deliv top bottom line beat ww tavr result came lighter
expect remain optimist acceler ww tavr trend driven
increas capac low risk creep valve-in-valv volum ramp deeper intermedi
risk penetr sentiment valuat reset repres opportun front
ew ww tavr growth came lower expect scrutin
manag continu confid acceler tabl
ww tavr sale guidanc upper end rang reiter
launch centera sapien ultra intern start continu
access program cite driver maintain outlook tavr
franchis experienc growth less estim mid-teen growth
market competitor aggress price initi led modest share loss
quarter tavr franchis grew mid-teen in-lin market importantli
eu market grew dd year sinc launch japan remain
strongest growth region ww tavr result make back-half weight year
growth need move north similar comp hit manag target
remain optimist deeper penetr intermedi risk indic low risk creep
tavr-in-savr valve-in-valv new center add higher clinic trial revenu
play low risk approv
tavr perform requir greater reacceler hit guidanc
rel ww tavr miss dampen investor sentiment especi context
similar narr follow result although assess ew tavr guidanc
still achiev see littl upsid ww tavr growth believ
stock reaction result express view acceler
ww tavr growth perform level essenti meet reiter target rang
high end growth said ew benefit sever catalyst
back half drive sequenti improv includ stronger contribut
centera eu unit sapien ultra approv eu launch higher
 clinic revenu continu access program/centera trial/
bicuspid risk registry/earli tavr/tavr unload also continu expect
deeper intermedi risk penetr low risk creep valve-in-valv new center aid
sequenti acceler expect ew multipl re-rat lower ww tavr result
weigh sentiment like creat overhang share pend stronger result
come quarter despit short-term volatil result remain believ
long term tavr growth trajectori view ew pipelin best in-class would remain
buyer front low risk data right around corner
pleas see page report import disclosur
base outperform rate belief sustain ew high-single-digit
double-digit top-lin growth along double-digit ep growth trajectori driver
compani includ tavr market leadership age global elderli popul shift
aortic stenosi risk curv tavr rais tavr awar among patient
expect last year fda ce mark approv sapien intermedi risk aid
upsid trial prove favor believ ew share continu valu
premium median forward price-to-earnings multipl compani large-cap peer churn
centera sapien ultra ce launch
intermedi risk market develop
wake surtavi data readout
updat mitral program timelin
maintain market share
top-lin growth acceler
us tavr market
top-lin growth deceler
strong adopt sapien high-risk/
ew mitral program develop faster
expect
inoper patient us
continu success roll-out sapien
intermedi risk
ew lead medic devic compani manufactur heart valv repair
product replac repair diseas defect heart compani also provid
hemodynam monitor system cardiovascular function measur hospit
set headquart irvin california ew oper roughli countri
employe world-wide compani found edward
laboratori acquir baxter spun baxter earli
ew sale product world-wide posit
ew reiter belief hit high end sale guidanc
high end compani sale guidanc rang repres
growth compar current street forecast confer
call thursday ew restat belief experi upper-end sale growth
three busi divis divis ew target
transcathet heart valv therapi reflect underli growth
includ roughli million mitral product sale compani model
share gain assumpt outlook thvt commentari manag
call benefit limit continu access program cap begin
market reintroduct centera europ late align start
 studi sapien ultra ce mark approv like end fda
approv year-end increas contribut mitral cardioband
roll-out ew set sale rang surgic heart valv
project critic care sale
unchang move incom statement percentag sale compani
continu expect full-year adjust gross margin sg
 manag note spend higher
ew rais full-year adjust ep guidanc time rang
previous compar current street
consensu ew anticip tax rate exclud special item
low end previous issu rang also expect lift
foreign exchang year previous respect
free cash flow compani continu expect full-year come
high end origin guidanc rang current foreign
exchang rate ew project total sale adjust
ep forecast compar current street estim
pipelin develop ew continu expect ultra ce mark approv
compani also remain confid time approv late centera
receiv ce mark februari approv pivot trial studi
centera sever symptomat aortic stenoi patient intermediate-risk
open heart surgeri manag also maintain expect commenc enrol
single-arm patient studi one-year endpoint includ
bicuspid patient sub-studi studi conduct edward center
therefor add increment expens without associ revenu enrol
cap program low-risk patient trial slate begin
partner trial ew plan present data next year march fda approv
low-risk indic later elsewher portfolio integr activ
harpoon medic acquisit continu although manag note still
examin root caus complic specif harpoon patient dynam
first discuss last quarter complic identifi patient
treat earli clinic studi mitral repair portfolio highlight cardioband
pascal harpoon three option bring differenti valu proposit
surgeon patient cardioband meant address patient annular dilat
pascal aim need leaflet repair harpoon target patient need
chord repair patient continu treat cardioband procedur
success rate remain high ew expect suppli product remain constrain
continu integr effort cardioband suppli chain
edward qualiti system manag maintain expect
cardioband sale pascal ce mark trial enrol also progress forward
manag anticip product launch europ ew track initi
 trial later year cardiaq sapien repres ew two mitral replac
program first-inhuman/earli feasibl studi way ultim
goal system reduc mr zero use safe transsept procedur
recap call promis earli clinic data present crt earlier year
reiter confid feasibl treatment patient sever mr
elev risk mitral valv surgeri
soft thvt result take shine top bottom line beat
ew post disappoint quarter despit revenu beat
consensu ep exceed consensu project thvt revenu
scrutin trail street estim
repres report growth underli tavr growth driven
continu momentum therapi adopt although ew estim lost share ou
price aggress competitor surgic heart valv therapi fare better revenu
surpass consensu figur shvt perform
driven new product growth exceed procedur growth critic revenu
similarli beat consensu number critic result led
strong growth across portfolio specif hemospher advanc monitor
platform region benefit new gpo contract geographi
ew underli growth europ japan
row gross margin lower consensu
estim estim larg result fx headwind
continu invest oper although factor partial
off-set favor product mix weaker gross margin off-set part lower
expect vs estim despit continu invest
transcathet heart valv program associ clinic studi adjust quarterli
tax rate also lower estim ew benefit
settlement tax audit tax plan stem tax reform ew oper
margin better estim consensu
translat ep also estim consensu
figur edward lifesci result vs cowen estim consensu
compani report thomson eikon cowen compani
chg chg chg heart heart good gross gross margin oper net interest expens net expens pre-tax incom tax incom tax net incom dilut share estimatesour estimatesactu cowen
compani report thomson eikon cowen compani
good basic share mm dilut share tax forma net forma ep incl net ep analysisgross analysistot forma cowen
compani report thomson eikon cowen compani
compani report thomson eikon cowen compani
usecent tavr enu cardioband enu total enu growth tavr enu growth cardioband growth trial/hd usequarterli clinic trial usecent commerci total commerci growth total enu growth q/q enu growth q/q non-royalti enu growth q/q pure commerci enu growth usecent commerci total worldcommerci usecent world ww enu cowen
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
continu util pressur account organ play bigger
role health care deliveri competit dynam global potenti regulatori delay
reject failur devic clinic trial econom sensit price pressur
and/or weaken consum demand develop market econom and/or polit
uncertainti emerg market intellectu properti challeng
potenti regulatori delay reject failur devic clinic trial econom
sensit price pressur and/or weaken demand develop market econom
and/or polit uncertainti emerg market setback develop tmvr
product prevent commerci fluctuat foreign exchang rate
